This study used the international SUROVA cohort to characterize two distinct clinical phenotypes in advanced ovarian cancer: early death (death shortly after diagnosis) and early relapse (relapse within a short interval after treatment), examining their clinical features, frequency, and outcomes.
Early death and early relapse were identified as distinct clinical phenotypes in advanced ovarian cancer, each with differing clinical characteristics and prognostic implications within the SUROVA cohort; specific numerical outcomes were not available in the provided abstract.
Full text was not available for review, limiting extraction of specific numerical results, subgroup definitions (e.g., exact timeframes for 'early'), and detailed methodology.
Clinicians managing advanced ovarian cancer should recognize early death and early relapse as separate clinical entities, as they likely require different risk-stratification and management approaches.
Explore related topics
